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A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)þleucovorin (LV)þoxaliplatin alternated
with UFT/LVþirinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-
free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no
cases of hand–foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients
with metastatic CRC.
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Recent developments in the treatment of colorectal cancer (CRC)
include the introduction of oral fluoropyrimidines, such as
tegafur/uracil (UFT) and capecitabine, which may replace infu-
sional 5-FU (Cunningham and James, 2001). Tegafur/uracil is a
fixed combination of tegafur (1-2(tetrahydrofuranyl)-5-fluorour-
acil) and uracil in a 1:4 molar ratio (Maehara et al, 1997): tegafur
is an orally bioavailable prodrug of 5-FU, and uracil reversibly
inhibits dihydropyrimidine dehydrogenase, the primary 5-FU
catabolic enzyme.
After the promising response rates reported in phase II, two
randomised trials of the UFT/leucovorin (LV) combination found
that it was as efficacious as conventional 5-FU/LV, but had a better
safety profile (Carmichael et al, 2002; Douillard et al, 2002).
Furthermore, the results of phase I/II studies of UFT/
LVþoxaliplatin (L-HOP) or UFT/LVþirinotecan (CPT-11) com-
binations indicate their favourable antitumour activity (Price and
Hill, 2000; Alonso et al, 2001; Vanhoefer and Wilke, 2001).
In order to increase the efficacy while minimising toxicity, we
designed a new chemotherapy protocol in which UFT/LV is
alternately combined with L-HOP and CPT-11. The aim of this
phase II study was to evaluate the antitumour activity and toxicity
of this new regimen in patients with metastatic CRC.
MATERIALS AND METHODS
Eligibility criteria
The eligibility criteria were histologically proven metastatic colon
or rectum adenocarcinoma, no previous chemotherapy for
metastatic disease, age 18–75 years, an ECOG performance status
of 0–2, bidimensionally measurable disease, a life expectancy of at
least 3 months, an absolute neutrophil count of X1.5 10
9l
 1 and
platelet count of X100 10
9l
 1, and creatinine and total bilirubin
levels p1.25 times the upper normal limit. Adjuvant 5-FU-based
chemotherapy had to be completed 46 months before entry.
The exclusion criteria were operable metastatic disease, severe
cardiac dysfunction, chronic diarrhoea or uncontrolled infection.
The study was approved by our local Ethics and Scientific
Committee; all of the patients gave their written informed consent.
Patient evaluation
The pretreatment evaluation included a detailed history and
physical examination, complete blood cell count, whole blood
chemistry, and chest and abdominal computed tomography (CT).
During treatment, the patients underwent weekly complete blood
cell counts, fortnightly clinical assessments, and routine biochem-
ical tests.
Response was evaluated after two 35-day cycles (sooner if
clinically indicated) using WHO criteria (Miller et al, 1981), and
confirmed after 4 weeks by means of repeat CT scans. The results
were reviewed by an independent Review Committee of three
radiologists blinded to the investigator’s measurements, whose
assessments were exclusively based on imaging techniques.
Toxicity was assessed using the NCI criteria. Treatment was
delayed if neutrophils were o1500mm
 3, platelets
o100000mm
 3, or the patient had persistent grade 41 diarrhoea
or stomatitis.
UFT intake was interrupted for grade 42 nonhaematological
toxicity, and not resumed until this was grade p1. The dose was
reduced by 50mgm
 2day
 1 in the treatment cycles following the
appearance of grade 3 or 4 haematological or nonhaematological
toxicities. If UFT was discontinued or doses were missed, LV was
not given. The study medication returned by the patient was
counted at each cycle.
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lAfter the appearance of grade X3 nonhaematological or grade 4
haematological toxicity, the L-HOP or CPT-11 dose was reduced by
25% in subsequent cycles. L-HOP was also reduced by 25% for
persistent (X14 days) paraesthesia or temporary (7–14 days)
painful paraesthesia or functional impairment. In cases of
persistent (X14 days) painful paraesthesia or functional impair-
ment, L-HOP was omitted from subsequent cycles until recovery.
Treatment
Oral UFT (250mgm
 2day
 1) and LV (90mgday
 1) were given for
28 days of a 35-day cycle, combined with a 2-h infusion of L-HOP
(85mgm
 2) on days 1 and 15. On day 35, the next cycle consisted
of oral UFT/LV at the same doses for 28 days, combined with a 90-
min infusion of CPT-11 (180mgm
 2) on days 35 and 49. The
treatments were alternated until disease progression, unacceptable
toxicity or consent withdrawal.
The total daily UFT dose was divided into three administrations
(rounded to the nearest 100mg) every 8h; if the doses could not be
divided equally, the highest was administered in the morning.
Intravenous (i.v.) 5-hydroxytryptamine-3 antagonists plus
dexamethasone 8mg i.v. were administered before the infusions.
No cytokine prophylaxis was recommended.
Statistical analysis
As at least 40% of patients respond to standard 5-FU/LVþCPT-11
or 5-FU/LVþL-HOP combinations, a 460% response to a new
regimen with acceptable toxicity can be considered promising.
Using Simon’s two-stage minimax design, with alpha and beta
error probabilities of 0.10, at least 41 patients were required
(Simon, 1989).
RESULTS
A total of 41 patients with metastatic CRC were enrolled between
September 2001 and January 2003 (Table 1). A total of 177
chemotherapeutic cycles were administered for a median of five
cycles/patient (range 2–8). All of the patients were assessable for
treatment response and toxicity.
Intent-to-treat analysis showed complete responses in three
patients (7.3%) and partial responses in 21 (51.2%): an overall
response rate of 58.5% (95% CI 42.2–73.3%) confirmed by an
independent radiological review. In all, 13 patients (31.7%) had
stable disease, and four (9.8%) progressive disease. The median
response duration was 7.1 months (range 3.2–16.4). Postche-
motherapy surgery of residual metastases was attempted in eight
patients (19.5%) with liver involvement only, and was macro-
scopically complete in four (9.8%). After the study, 12 patients
received second-line chemotherapy with mitomycin and six a
weekly 5-FU/LV bolus.
The median follow-up was 15.6 months; median progression-
free survival (PFS) 8.8 months (95% CI: 7.4–10.2); median overall
survival 17.3 months (95% CI: 14.6–20.4) (Figure 1).
Treatment toxicity
There were no grade 4 toxicities; grade 3 toxicity was uncommon
except for diarrhoea (Table 2). The patients were all treated as
outpatients, and none was hospitalised because of adverse events.
No cardiac or vascular toxicity was observed, and no cases of
hand–foot syndrome. Three patients (7%) showed increased
bilirubin levels (grade 2–3) unassociated with concurrent severely
increased transaminases; all resumed treatment after recovery.
During treatment, 6% of the cycles were associated with grade 3
diarrhoea, 3% with grade 3 neutropenia, and 2% with grade 3
nausea/vomiting. Diarrhoea peaked in cycle 2, and was reduced in
the following cycles by dose adaptations.
Drug exposure
The median received cumulative dose intensity was 32gm
 2 for
the fluoropyrimidine, 470mgm
 2 for L-HOP, and 640mgm
 2 for
CPT-11. The median received dose intensities during the first two
cycles were, respectively, 1372 (98% of planned), 16.6 (98%), and
34.9mgm
 2week
 1 (97%).
In all, 12 patients (29%) and 21 cycles (12%) required dose
reductions of at least one drug. A total of 34 cycles (19%) were
delayed by 41 week because of diarrhoea (9%), neutropenia (2%),
Table 1 Patient characteristics
Characteristic No. of patients (n¼41) %
Age (years)
Median 65
Range 46–75
Sex
Male 23 56
Female 18 44
ECOG performance status
02 7 6 6
11 0 2 4
24 1 0
Primary tumour
Colon 34 83
Rectum 7 17
Previous primary tumour surgery 35 85
Metastatic sites
Liver 36 88
Lung 7 17
Lymph nodes 8 20
Local abdominal mass 7 17
Peritoneum 4 10
Bone 1 2
Pleural effusion 1 2
No. of metastatic sites
12 2 5 4
21 6 3 9
433 7
Previous adjuvant chemotherapy 16 39
Previous adjuvant radiotherapy 3 7
100
80
60
40
20
0
0 3 6 9 12 15 18 21
Months
%
 
o
f
 
P
a
t
i
e
n
t
s
 
f
r
e
e
 
o
f
 
p
r
o
g
r
e
s
s
i
o
n
a
n
d
 
s
u
r
v
i
v
i
n
g
Entered Progressed Dead
41 32 19
Figure 1 Kaplan–Meier curves for progression-free survival ( ) and
overall survival ( ).
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lother toxicities (2%), or reasons unrelated to the treatment (6%).
Tegafur/uracil was interrupted for a median of 3 days (range: 1–7)
in 33% of the cycles, because of diarrhoea or other toxicities.
DISCUSSION
Our results indicate the feasibility and efficacy of UFT/LVþL-
HOP alternated with UFT/LVþCPT-11 in non-pretreated meta-
static CRC patients. This regimen predictably meant low dose
intensities of L-HOP (planned 17mgm
 2week
 1) and CPT-11
(planned 36mgm
 2week
 1), but our results (58.5% response rate)
and other recent clinical data suggest that prolonged tumour
exposure to a fluoropyrimidine plus full doses of L-HOP alternated
with full doses of CPT-11 can be highly efficacious in metastatic
CRC (Aschele et al, 2002; Aparicio et al, 2003). Comparison of this
small phase II study with similar experiences including other oral
drugs such as capecitabine is difficult, above all because of their
different schedules. A fixed UFT dose of 250mgm
 2day
 1 for 28
days was chosen on the basis of the proved activity and tolerability
of continuous administration and the results of previous phase I/II
studies (Twelves, 1999; Price and Hill, 2000; Vanhoefer and Wilke,
2001). A biweekly schedule was chosen for CPT-11 or L-HOP
because it is active and has a favourable toxicity profile (de
Gramont et al, 2000; Douillard et al, 2000).
More than 50% of our patients were chemonaive, only four had
peritoneal disease, and 66% had an ECOG performance status of 0,
thus indicating a better than average group with regard to efficacy
and toxicity. Furthermore, the CR rate remained low (7.3%) and, if
an increase in the rate of CR or PFS cannot be achieved by
combining all the three active compounds in one regimen, much
can be said in favour of sequential treatment regimens.
Our alternating regimen was well tolerated as the proportion of
patients with grade 3 diarrhoea (29%) was only slightly
higher than that reported with UFT/LV alone. Grade 3 diarrhoea
was most frequent during cycle 2, which suggests a cumulative
component and/or overlapping toxicity with CPT-11.
The low level of haematological toxicity was mainly due
to the choice of an alternating regimen, which favours safety (no
overlapping toxicity) at the expense of dose intensity. Nevertheless,
a high incidence of severe neutropenia, associated with
greater use of haematopoietic growth factors, is often reported
when 5-FU, L-HOP, and CPT-11 are simultaneously combined
(Falcone et al, 2002; Souglakos et al, 2002). Hand–foot syndrome,
which is frequently described with the use of continuous
5-FU infusions or capecitabine (Van Cutsem et al, 2000), was
never observed, possibly because the profile of frequent oral UFT/
LV dosing may resemble that of a repeated mini-bolus (Ho et al,
1998) and the UFT dose (250m
 2day
 1) was lower than the 300–
350mgm
 2day
 1 used by other authors. The complete absence of
hand–foot syndrome is very promising and a major
advantage over similar studies of capecitabine. However, only a
randomised trial can clarify the question as to whether capecita-
bine or UFT is the best oral 5-FU drug for combination
chemotherapy.
The low level of neurotoxicity was due to the low median
cumulative L-HOP dose per patient (470mgm
 2), and the fact that
a biweekly schedule of a dose of 85mgm
 2 in a 2-h infusion may
minimise the symptoms of chronic cumulative neuropathy
(Cassidy and Misset, 2002).
In conclusion, our findings suggest that the combination of
UFT/LVþL-HOP alternated with UFT/LVþCPT-11 is an effective
and well-tolerated regimen for the first-line treatment of metastatic
CRC.
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